

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

AG

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 7 :</b> <b>C12N 15/12, C07K 14/47, A61K 38/17</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/70043</b> <b>(43) International Publication Date:</b> 23 November 2000 (23.11.00)
<b>(21) International Application Number:</b> PCT/DK00/00246 <b>(22) International Filing Date:</b> 10 May 2000 (10.05.00)  <b>(30) Priority Data:</b> PA 1999 00668 14 May 1999 (14.05.99) DK PA 1999 01508 20 October 1999 (20.10.99) DK  <b>(71)(72) Applicants and Inventors:</b> THIEL, Steffen [DK/DK]; Villadsensvej 3, DK-8240 Risskov (DK). JENSENIUS, Jens, Christian [DK/DK]; Finsens Allé 28, DK-5230 Odense (DK). JENSEN, Thomas, Vorup [DK/DK]; Fåborggade 14, DK-8000 Århus C (DK).  <b>(74) Agent:</b> HØIBERG APS; Nørre Farimagsgade 37, DK-1364 Copenhagen K (DK).		<b>(81) Designated States:</b> AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> RECOMBINANT HUMAN MANNAN-BINDING LECTIN  <b>(57) Abstract</b> <p>The present invention relates to treatment of diseases and disorders of the immune system comprising treatment of deficiencies within the immune defence system. The invention concerns preparation of a novel expression construct encoding human MBL, a novel recombinant preparation of human MBL with high similarity to natural human MBL and furthermore it comprises use of this compound in compositions, medicaments and in methods for treatment of conditions such as those related to immunosuppressive conditions and/or to conditions of MBL deficiencies including latent conditions. Conditions of deficiencies of Mannan-Binding Lectin (MBL) are associated with increased susceptibility to infections. In more particular, the invention concerns treatment of said conditions, including latent conditions, i.e. although there is no present need. The treatment is aimed at humans and at animals, in which the immune system appears to act similarly to the human immune system.</p>		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## Recombinant Human Mannan-Binding Lectin

The invention relates to a process for preparing a composition comprising MBL, and treatment of diseases and disorders of the immune system comprising treatment of deficiencies within the immune defence system. In more particular, the invention concerns treatment of conditions or latent conditions of deficiencies of Mannan-Binding Lectin (MBL) which is associated with increased susceptibility to infections. The invention further concerns preparation of a novel expression construct encoding human MBL, a novel recombinant preparation of human MBL and furthermore it comprises use of this compound in methods for treatment of conditions such as those related to immunosuppressive chemotherapy and/or conditions of MBL deficiencies including latent conditions, i.e. not in a present need. The treatment are aimed at humans and at animals, in which the immune system appears to act similarly to the human immune system.

## BACKGROUND OF THE INVENTION

The immune system comprises a complex array of cellular and molecular mechanisms which recognises and targets pathogenic microorganism or the cells infected with them. Recently, MBL has gained great interest as an important part of the innate immune system, that is, the immune system which at time of birth is operational, in contrast to the adaptive immune defence which only during infancy obtains its full power of protecting the body (Janeway *et al.*, 1999). Upon binding of carbohydrates of microbial surfaces, MBL mediates activation of the complement cascade, a series of enzymatic activation steps, which eventually label the target for destruction by phagocytosis or by lysis of the microorganism (Law & Reid, 1995). The complement system is being activated through at least three distinct pathways, designated the classical pathway, the alternative pathway, and the MBlectin pathway (Janeway *et al.*, 1999). The classical pathway is initiated when complement factor 1 (C1) recognises surface-bound immunoglobulin. The C1 complex is composed of two proteolytic enzymes, C1r and C1s, and a non-enzymatic part, C1q, which contains immunoglobulin-recognising domains. C1q and MBL shares structural features, both molecules having a bouquet-like appearance when visualised by electron microscopy. Also, like C1q, MBL is found in complex with two proteolytic

CONFIRMATION COPY

enzymes, the mannan-binding lectin associated proteases (MASP). The three pathways all generate a convertase of complement factor 3 (C3 convertase) bound to the surface of the activating surface, *i.e.*, the targeted microbial pathogen. Conversion of C3 into surface bound C3b is pivotal in the process of eliminating the microbial pathogen by phagocytosis or lysis (Janeway *et al.*, 1999).

Mannan-binding lectin (MBL), also named mannan-binding protein or mannose-binding protein (MBP), was first characterised in rabbits (Kawasaki *et al.*, 1978). Mannan-binding lectin (MBL) belongs to a group of soluble  $\text{Ca}^{2+}$ -dependent (C-type) lectins containing a C-terminal carbohydrate recognition domain and a collagen-like region characterised by repeated triplet-motifs of glycine (Gly) followed by two non-glycine amino acids. Thus, MBL belongs to the group of collectins, *i.e.*, C-type lectins with collagen-like regions, which in addition comprises the lung surfactant proteins A and D as well conglutinin and CL-43, these, however, only having been characterised in cattle (Holmskov *et al.*, 1994). The human MBL protein is composed of up to 18 identical 32 kDa polypeptide chains (Lu *et al.*, 1990), each comprising a short N-terminal segment of 21 amino acids including three cysteine residues, followed by 7 repeats of the collagenous motif Gly-X-Y interrupted by a Gln residues followed by another 12 Gly-X-Y repeats. A small 34 residue 'neck-region' joins the C-terminal  $\text{Ca}^{2+}$ -dependent lectin domain of 93 amino acids with the collagenous part of the molecule (Sastry *et al.*, 1989). Three MBL polypeptide chains are joined in a MBL subunit. MBL consists of up to six 15 nm stalks of MBL subunits joined at the base of the bouquet. Later work characterised MBL in rodents (Mizuno *et al.*, 1981; Oka *et al.*, 1988), cattle (Holmskov *et al.*, 1993a; Kawai *et al.*, 1997), and chicken (Oka *et al.*, 1985; Laursen *et al.*, 1995; Laursen *et al.*, 1998). In rodents (Drickamer *et al.*, 1986) and rhesus monkeys (Mogues *et al.*, 1996) two types of *MBL* genes have been identified, usually designated as A and C forms. In rats, an MBL 'B' pseudogene was found (Drickamer *et al.*, 1986) and recently an MBL pseudogene was also cloned from the human genome, sequence analysis suggesting this to be remnants of a primate *MBL-A* gene (Guo *et al.*, 1998). Human MBL was characterised by Kawasaki *et al.* in 1983. Only one active human MBL gene has been identified, comprising four exons with three intervening introns of the *MBL* gene spanning approximately 6 kb and is located at 10q11.2-q21 (Sastry *et al.*, 1989; Taylor *et al.*, 1989).

The collagenous regions of the three polypeptide chains combine to form a subunit which is stabilised covalently by disulphide bridges. Individual subunits are joined by disulphide bridges as well as by non-covalently interactions (Lu *et al.*, 1990).

5     The position of these disulphide bridges has, however, not been fully resolved. SDS-PAGE analysis under non-reducing conditions of MBL shows bands with an apparent molecular weight (m.w.) larger than 200 kDa presumably representing blocks of 3, 4, 5 and even 6 assembled subunits (Lu *et al.*, 1990).

10    The actual number of subunits in the natural human MBL protein has been controversial. Lipscombe *et al.* (1995) obtained data by use of ultracentrifugation suggesting 25% of human serum MBL to be made of 2-3 subunits and only a minor fraction reaching the size of 6 subunits. The relative quantification was carried out by densitometry of Western blots developed by chemiluminescence. Lower efficiency in  
15    transferring high molecular weight protein onto membranes compared to proteins of lower molecular weight make analysis through this methodology complicated. Lu *et al.* (1990) found by SDS-PAGE analysis of fractions from ion exchange chromatography that the predominant species of covalently linked MBL subunit chains consisted of tetramers while only pentameric or hexameric complexes activated complement. Gel permeation chromatography (GPC) analysis, in contrast, suggests that  
20    MBL is comparable in size with the C1 complex. GPC can be carried out under conditions which allow for a study of the importance of weak protein-protein interactions in the formation of MBL molecules and, in combination with standard MBL assay techniques, also allows for unbiased determination of the MBL content in the GPC  
25    fractions.

The *in vivo* role of MBL seems mainly to relate to the innate immune system as a humoral factor mediating some anti-microbial activity, which does not require maturation into self/non-self discrimination like the adaptive immune defence system  
30    based on T- and B-cell recognition (Janeway *et al.*, 1999; Vorup-Jensen *et al.*, 1998). The recognition of targets for MBL binding is mediated by the C-type lectin domain. C-type CRDs are found in proteins with a widespread occurrence, both in phylogenetic and functional perspective. In the case of MBL, the CRD recognises preferentially hexoses with equatorial 3- and 4-OH groups, such as mannose and N-

acetyl glucosamine while carbohydrates which do not fulfil this sterical requirement, such as galactose and D-fucose, are not bound (Weis *et al.*, 1992).

5 The terminal CRDs are distributed in such a way that to allow for binding of all three domains target surfaces should present binding sites with a spacing of approximately 53 Å (Sheriff *et al.*, 1994; Weis & Drickamer, 1994). This property of 'pattern recognition' may contribute further to the selective binding of microbial surfaces. The carbohydrate selectivity is obviously an important aspect of the self/non-self discrimination by MBL and is probably mediated by the difference in prevalence of mannose and N-acetyl glucosamine residues on microbial surfaces, one example being the high content of mannose in the cell wall of yeasts such as *Saccharomyces cerevisiae* and *Candida albicans*. Carbohydrate structures in glycosylation of mammalian proteins are usually completed with sialic acid, which prevents binding of MBL to these oligomeric carbohydrates and thus prevents MBL recognition of 'self' surfaces. Also, the trimeric structure of each MBL subunit may be of importance for target recognition.

Several studies have been carried out on aspects of the structure and biosynthesis of MBL by use of *in vitro* synthesis systems. The structure of the CRD of rat MBL-A was resolved by crystallising recombinant protein produced in *E. coli* (Weis *et al.*, 1992), and the structure of rat MBL-C has likewise been resolved by use of recombinant material (Ng *et al.*, 1996). More recently, the crystal structure of the trimer of CRDs assembled through expressing both the 'neck-region' and the CRD have confirmed the earlier studies on the 'neck-region' as bringing together the three chains by hydrogen bonds between the coiled-coil  $\alpha$ -helices (Sheriff *et al.*, 1994; Weis & Drickamer, 1994). The CRDs and 'neck-CRD' fragments of other collectins have likewise been expressed in *E. coli* based systems without the requirement of refolding protocols to gain functional activity. Thus, the *in vitro* synthesis of MBL domains can both with regard to the functional properties of carbohydrate recognition and the structural property of trimerisation efficiently be carried out in prokaryotic or simple eukaryotic expression systems.

*In vitro* synthesis of complete collectins by recombinant technique have mainly been attempted by use of mammalian cell lines, e.g., CHO and COS cells, as host cells. Attempts to express MBL in insect cells only resulted in low m.w. MBL (Ma *et*

*et al.*, 1996), the recombinant proteins almost entirely consisting of subunits, dimers, and trimers of the MBL subunit chains.

5 Recombinant synthesis of human MBL in mammalian cell lines have been reported in several studies. In a study on opsonic function *i.e.*, ability to enhance uptake by macrophages, of MBL, Kuhlman *et al.* (1989) used rMBL produced in CHO cells, which showed the same opsonic activity, as natural MBL. Characterisation of the rMBL with regard to structure and post-translational modifications was not carried out. Likewise, Schweinle *et al.* (1993) produced rMBL and a truncated form of rMBL  
10 lacking the collagenous tail by stable transfection of CHO cells. Activity of the recombinant proteins was measured by C3 deposition on *Salmonella montevideo* preincubated with MBL and diluted human serum depleted of antibodies against *S. montevideo* as complement source. Surprisingly, the activity of recombinant full-length MBL was as high as for natural MBL though analysis of iodinated rMBL by  
15 ultracentrifugation showed the majority of the protein to be low molecular weight material. Comparison of the CHO cell produced rMBL with natural MBL concerning size, either through SDS-PAGE, ultracentrifugation or GPC, was not included. In a study by Super *et al.* (1992), GPC profiles of rMBL produced in mouse Sp2/0Ag14 hybridoma cells were presented indicating that the size distribution of rMBL purified  
20 from the culture supernatant by carbohydrate affinity chromatography was markedly different from rMBL isolated through anti-MBL antibody affinity chromatography with respect to size distribution.

25 Recently, Ohtani *et al.* (1999) published data on human rMBL produced in CHO cells, which gave a yield of 120 µg per mL of culture medium. This was obtained using a expression vector allowing for selection of transfectants by G418 resistance and subsequent gene amplification through selection with methionine sulfoximine (MSX). Functional activity concerning carbohydrate selectivity was identical to the natural protein whereas some differences in the ability to activate complement was  
30 found as measured through lysis of erythrocytes. Both the GPC and SDS-PAGE analysis showed the presence of higher molecular weight forms of MBL though the total size distribution was noted by the authors to differ significantly from MBL purified from plasma. Interestingly, the hydroxylation pattern was essentially identical to natural MBL even in the absence of added ascorbic acid. Concerning the post-

translation modifications, it should be noted from this study that proper hydroxylation of rMBL does not warrant a structure similar to natural MBL.

5 The human MBL locus is polymorphic with three known mutations located in the protein encoding region (Sumiya *et al.*, 1991; Lipscombe *et al.*, 1992a; 1992b; Madsen *et al.*, 1994) and others affecting regulatory elements of the gene (Madsen *et al.*, 1995). All mutations apparently leads to a significantly lower level of MBL in body fluids from affected individuals. The spread in MBL concentration as measured in serum is thus about three orders of magnitude, ranging from 2-5 µg MBL/mL to less than 10 ng MBL/mL in individuals homozygous for the mutations affecting protein coding regions. The finding of MBL deficiency being associated with recurrent infections in children which were diagnosed as suffering from an opsonic defect (Super *et al.*, 1989; Sumiya *et al.*, 1991) emphasised the correlation between insufficient MBL levels and reduction in the defence against micro-organisms. In addition to the interaction with micro-organisms, collectins have also been suggested to mediate anti-viral defence (Hartshorn *et al.*, 1993; Malhotra *et al.*, 1994). *In vitro* studies on interaction with human immunodeficiency virus (HIV) showed MBL to inhibit infection of CD4 positive T and U937 cells. Clinical studies also suggest a role for MBL as a first-line defence against HIV. The period of time from the onset of symptoms of AIDS until the terminal stage seem to differ between MBL-deficient patients and patients with normal MBL levels. Also, the susceptibility to contract the infection appears to be significantly higher among MBL-deficient individuals as MBL deficiency occurs more frequently among HIV infected patients than healthy controls (Nielsen *et al.*, 1995; Garred *et al.*, 1997a). Hereditary complement deficiencies contribute to development of systemic lupus erythematosus (SLE) as have been shown for cases of C1, C2, and C4 deficiency (reviewed by Tan & Arnett, 1998). Several studies have suggested MBL deficiency likewise to be a risk factor in development of SLE (Davies *et al.*, 1995; Lau *et al.*, 1996; Ip *et al.*, 1998) although the role of MBL is not well defined. One suggestion, following explanations for the other complement deficiencies as causative agents in SLE, argues that the defect in complement fixation due to MBL deficiency leads to poor immune complex clearance (Ip *et al.*, 1998), thus pointing to MBL as a participant in maintaining homeostasis. Other clinical evidence suggests MBL to play an important role in reproductive biology. Recent reports show association between recurrent miscarriages and the MBL level (Kilpatrick *et al.*, 1995; Christiansen *et al.*, 1999).



A strategy for treating symptomatic MBL insufficient individuals aiming at reconstituting the MBL pathway has only been described in two studies. An opsonic defect observed among some children, at the time only characterised by the clinical manifestation of frequent infections, was treated by administering plasma (Soothill & Harvey, 1976) while, in a more recent study, plasma-derived MBL was injected into a two-year-old girl (Valdimarsson *et al.*, 1998). In both studies a health improvement was reported though the small number of patients involved in these studies obviously limits conclusions with regard to MBL as therapeutic agent. No clinical studies have been conducted with rMBL. A study by Ma *et al.* (1999) showed an antitumor activity of rMBL in mice mediated by a virus expression system.

As appears from the above, several attempts have been made to produce rMBL in in vitro systems in a form either identical to or with a high degree of resemblance to the natural protein. However, significant limitations have been demonstrated in the ability of the presently known in vitro synthesis systems to produce such rMBL.

#### SUMMARY OF THE INVENTION

In one aspect the present invention provides a novel form of MBL that is prepared by recombinant DNA technology in vitro or in vivo. More specifically, the invention concerns recombinant MBL (rMBL) in a novel form, which the inventors surprisingly found could be synthesized by the following process:

A process of producing a human recombinant mannan binding lectin (MBL) composition having a size distribution profile at least 50 % identical to naturally occurring human MBL, comprising the steps of:

- preparing a gene expression construct encoding human MBL peptide or a functional equivalent thereof,
- transforming a host cell culture with the construct,
- cultivating the host cell culture, thereby obtaining expression and secretion of the polypeptide into the culture medium, followed by

- 5     subjecting said culture medium to affinity chromatography using a carbohydrate-derivatized matrix, said carbohydrate-derivatized matrix having at least a two-fold greater affinity for tetramers, pentamers, and/or hexamers of MBL subunit than for dimers of MBL subunits.
- obtaining an eluate comprising the human recombinant MBL composition.

10     By a functional equivalent to human MBL is meant a molecule having the function of human MBL, e.g., binding to microbial carbohydrates, mediating opsonising activity and/or activating complement as may be demonstrated by C4 deposition on a mannan-coated surface

15     The functional activity of MBL may be estimated by its capacity to form an MBL/MASP complex leading to activation of the complement system. When C4 is cleaved by MBL/MASP an active thiol ester is exposed and C4 becomes covalently attached to nearby nucleophilic groups. A substantial part of the C4b will thus become attached to the coated plastic well and may be detected by anti-C4 antibody.

20     A quantitative TRIFMA for MBL functional activity was constructed by 1) coating microtitre wells with 1 mg mannan in 100 ml buffer; 2) blocking with Tween-20; 3) applying test samples, e.g. diluted MBL preparations 4) applying MBL deficient serum (this leads to the formation of the MBL/MASP complex); alternatively the MBL and the MBL deficient serum may be mixed before application with the microtitre  
25     wells; 5) applying purified complement factor C4 at 5 mg/ml; 6) incubate for one hour at 37°C; 7) applying Eu-labelled anti-C4 antibody; 8) applying enhancement solution; and 9) reading the Eu by time resolved fluorometry. Between each step the plate is incubated at room temperature and washed, except between step 8 and 9.

30     Estimation by ELISA may be carried out similarly, e.g. by applying biotin-labelled anti-C4 in step 7; 8) apply alkaline phosphatase-labelled avidin; 9) apply substrate; and 10) read the colour intensity. A calibration curve can be constructed using dilutions of one selected normal plasma. In relation to the present invention the following serum is an example of useful serums: plasma pool LJ 6.57 28/04/97. The func-

tionality may be expressed as the specific activity of MBL, such as in units of MBL activity per ng MBL.

5 Another assay for determining a functional equivalent to MBL is to determine the ability to bind to receptor/receptors on cells.

The interaction of MBL with receptor/receptors on cells may be analysed by cyto-fluorimetry. 1) MBL at a concentration of 50 µg/ml is incubated with 2x10<sup>5</sup> cells. The binding is carried out in phosphate buffered salt solution (PBS) containing 1% FCS and 0.1% Na-azide. 2) For detection of cell-bound MBL, biotinylated anti-MBL  
10 antibody is applied; 3) followed by the addition of streptavidin-FITC and 4) analysis of the mixture by fluorimetry.

15 A functional equivalent according to the invention fulfils at least one of the criteria discussed above, i.e. either activation of C4 or interaction with receptor(s) on cells, respectively. In a preferred embodiment both criteria are fulfilled.

By "recombinant human MBL" is meant human MBL which is expressed from engineered nucleic acids and by "MBL gene expression constructs" is meant an expres-  
20 sion vector suitable for expression in the host cells.

By the term "composition having a size distribution profile at least 50 % identical to naturally occurring human MBL" is meant that the size distribution of the various oligomers of MBL is 50 % identical on SDS-PAGE to human MBL purified from plasma by use of carbohydrate affinity chromatography. By 50 % identical is meant  
25 that at least 50 % of the oligomers has an apparent molecular weight higher than 200 kDa, when analysed by SDS-PAGE and/or Western blot. In determination of the amount of MBL having an apparent molecular weight higher than 200 kDa densitometric analysis may be used wherein protein bands on a SDS-PAGE gel is stained  
30 with protein-staining, e.g. silver staining or Coomassie Blue staining, or specific staining of Western blot using an MBL specific antibody.

By "purified recombinant MBL" is meant recombinant MBL purified from culture supernatants or body fluids or tissue from transgenic animals by use of carbohydrate  
35 affinity chromatography.

The present invention provides a form of MBL which is similar to natural human MBL, in that it in its purified form has a molecular size distribution profile closer to the natural human MBL than known up till now. Thus, in another aspect the invention relates to a recombinant human MBL composition comprising oligomers of MBL subunits, the size distribution profile of the oligomers being at least 50 % identical to the size distribution of naturally occurring plasma human MBL.

In the present context the term "oligomer" refers to the various "mers" of MBL, such as monomer, dimer, trimer, tetramer, pentamer and hexamer. The monomer consists of three identical peptide chains, in the present context referred to as a subunit. The other oligomers are formed as combinations of 2-6 subunits.

As to expression of rMBL, the invention relates to a gene expression construct encoding a recombinant human mannan-binding lectin (MBL) polypeptide, comprising

- at least one intron sequence from the human MBL gene or a functional equivalent thereof,
- at least one exon sequence from the human MBL gene or a functional equivalent thereof,
- a promoter region different from the human MBL promoter, and
- an expression vector.

The expression is preferably carried out in e.g. mammalian cells, the preparation according to the invention results from the use of an expression vector comprising intron sequence(s) from an MBL gene and at least one exon sequence. Regarding the transgenic animals as expression system this term is in this context animals which have been genetically modified to contain and express the human MBL gene or fragments or mimics hereof.

By "recombinant MBL with structural properties under non-denaturing similar to natural human MBL" is meant recombinant MBL eluting similarly from gel permea-

tion chromatography analysis as human MBL as present in serum. By "recombinant MBL with structural properties under denaturing conditions similar to natural human MBL" is meant purified MBL with a size distribution on SDS-PAGE 50% identical to human MBL purified from plasma by use of carbohydrate affinity chromatography (as illustrated by Fig. 1). Thus, by "recombinant MBL" is meant MBL substantially free from any impurities naturally associated with MBL purified from plasma.

In this regard, mannose associated serine proteases (MASP's) are not regarded as impurities.

Accordingly, in another aspect the present invention relates to a process of producing a human recombinant mannan binding lectin (MBL), comprising the steps of:

- preparing a gene expression construct as defined above encoding a human MBL polypeptide or a functional equivalent thereof,
- transforming a host cell culture with the construct,
- cultivating the host cell culture, thereby obtaining expression and secretion of the polypeptide into the culture medium, followed by
- obtaining a culture medium comprising human recombinant MBL.

Also an aspect of the present invention is a process for isolating or purifying human MBL in order to obtain a composition of polypeptides having a size distribution which is at least 50 % identical with naturally occurring human MBL.

Thus, the invention relates to a process of isolating a composition of human MBL oligomers having a size distribution at least 50 % identical with naturally occurring plasma MBL comprising

- obtaining a preparation of human MBL oligomers,
- subjecting said preparation to affinity chromatography using a carbohydrate-derivatized matrix, said carbohydrate-derivatized matrix having a two-fold

greater affinity for tetramers, pentamers, and/or hexamers of MBL subunit than for dimers of MBL subunit, and

- 5       - obtaining an eluate comprising the isolated human recombinant MBL composition.

10       In another aspect the invention concerns MBL, including rMBL, fragments or mimics hereof for use in the treatment of cancer and of conditions of diseases and disorders of eg the immune system and reproductive system, said treatment consisting of  
15       creation, reconstitution, enhancing and/or stimulating the opsonizing and bactericidal activity of the complement system, ie enhancing the ability of the immune defence to recognise and kill microbial pathogens. The application of rMBL similar to natural MBL in said treatment represents a great advantage over the application of known MBL, in particular plasma-derived human MBL, since the treatment with  
15       rMBL confers a much reduced risk of viral infection.

20       Said treatment may comprise cure and/or prophylaxis of diseases, disorders and/or conditions in need of treatment of cancer and of conditions of diseases and disorders of e.g. the immune system and reproductive system by humans and by animals  
20       having said functional units acting in this respect like those in humans. By condition in need of treatment is to be understood any condition in connection with current and/or expected need or in connection with an improvement of a normal condition. In particular, the treatment is a treatment of a condition of deficiency of MBL.

25       The invention further comprise pharmaceutical compositions containing MBL prepared according to the invention.

30       In yet an aspect the present invention concerns the use of MBL prepared according to the invention including fragments or mimics hereof, in the manufacture of a medicament or a pharmaceutical composition for the treatment comprising cure and/or prophylaxis of conditions of diseases and disorders of eg the immune system and reproductive system by humans and by animals having said functional units acting like those in humans.

Said diseases, disorders and/or conditions in need of treatment with the compounds of the invention comprise eg treatment of conditions of deficiency of MBL, treatment of cancer and of infections in connection with immunosuppressive chemotherapy including in particular those infections which are seen in connection with conditions during cancer treatment or in connection with implantation and/or transplantation of organs. The invention also comprises treatment of conditions in connection with recurrent miscarriage.

#### DETAILED DESCRIPTION OF THE INVENTION

10

The immune system has a considerable ability to prevent infections, which is of decisive importance for homeostasis and consequently survival and preservation of life. Therefore it is of considerable interest to identify compounds that are active in such processes. An intense research within this decade has uncovered Mannan-Binding Lectin (MBL) as a very versatile macromolecule, which eg is believed to be active in the innate immune system.

15

By the present invention it is possible to produce a human recombinant mannan binding lectin (MBL) composition having a size distribution profile at least 50 % identical to naturally occurring human MBL, as described above.

20

The MBL composition is produced as described above and subjected to an affinity chromatography capable of separating higher oligomers of MBL from the other oligomers.

25

The culture medium comprising a variety of MBL oligomers is subjected to an affinity chromatography on a carbohydrate-derivatized matrix.

30

Affinity chromatography is a well-known method for purifying proteins from a protein mixture. The carbohydrate-derivatized matrix has an least two-fold greater affinity for tetramers, pentamers and/or hexamers of MBL subunits than for dimers of MBL subunits. In a preferred embodiment the carbohydrate-derivatized matrix has an least three-fold greater affinity for tetramers, pentamers and/or hexamers of MBL subunits than for dimers of MBL. Also, the carbohydrate-derivatized matrix may

have an least two-fold greater affinity for tetramers, pentamers and/or hexamers of MBL subunits than for MBL subunits.

5        Thereby a MBL-composition having a size distribution being at least 50 % identical, such as 60 % identical, such as 70 % identical, such as 80 % identical, such as 90 % identical, such as 95 % identical, to naturally occurring MBL is provided. The size distribution is preferably substantially identical to naturally occurring MBL, whereby is meant that the identity is at least 99 %.

10       The carbohydrate-derivatized matrix has substantially no affinity to subunits and/or dimers of MBL subunits. Preferably the carbohydrate-derivatized matrix has affinity for substantially only tetrameric, pentameric and/or hexameric recombinant MBL subunits.

15       It is preferred that the higher oligomers of the subunit, such as tetramers, pentamers and/or hexamers are dominating the composition. Thus, in the composition the ratio of tetramers, pentamers, and/or hexamers to subunits and/or dimers is preferably at least 2:1, preferably at least 5:1.

20       In a preferred embodiment, the ratio of the sum of tetramers, pentamers and hexamers to the sum of subunits and dimers is preferably at least 2:1, more preferably at least 5:1.

25       The matrix may be derivatized with any carbohydrate or carbohydrate mixture whereto MBL binds and for which binding of the higher oligomers of MBL are favoured. The matrix is preferably a hexose-, such as a mannose- or a N-acetylglucosamin derivatized matrix, such as most preferably a mannose matrix.

30       The selectivity of the carbohydrate-derivatized matrix is obtained by securing that the matrix as such, i.e the un-derivatized matrix has substantially no affinity to MBL subunits, in particular no affinity to MBL trimers or smaller oligomers. This may be ensured when the matrix as such is carbohydrate-free. In particular the matrix should not contain any Sepharose or the like. It is preferred that the matrix consists of a non-carbohydrate-containing polymer material, such as Fractogel® TSK beads

35



The matrix may be in any form suitable for the chromatography, mostly in the form of beads, such as plastic beads.

5 After application of the culture media the column is washed, preferably by using non-denaturing buffers, having a composition, pH and ionic strength resulting in elimination of proteins, without eluting the highed oligomers of MBL. Such as buffer may be TBS. Elution of MBL is performed with a selective desorbing agent, capable of efficient elution of highed oligomers of MBL, such as TBS containing a desorbing agent, such as EDTA (5 mM for example) or mannose (50 mM for example), and  
10 MBL oligomers are collected.

According to the invention, the sequences from the MBL gene may be from the human MBL gene or from MBL genes of other animal species, in which the immune system in this respect is acting like the human immune system. An example of a  
15 preferred embodiment of a preparation of a recombinant MBL according to the invention is described in example 1 below, wherein said recombinant MBL is prepared by the use of an expression vector comprising sequences from the human *MBL* gene. An illustration of the expression vector in said preferred embodiment of the preparation method can be found in example 1 and in Figure 2.

20

The invention also concerns the use of expression vectors comprising sequences, which are functional derivatives of the sequences of the human MBL gene. By said functional derivatives are meant sequences, which contain base pair alterations that lead to no functional or essentially no functional differences of the expression vector and the in this way prepared MBL has a functionality comparable to the MBL prepared by the use of an expression vector comprising the unaltered sequences from  
25 the human MBL gene.

In addition to the purification method it is preferred that the gene expression construct and the host cell also favours production of higher oligomers.  
30

Accordingly, the gene expression construct preferably comprises at least one intron sequence from the human MBL gene or a functional equivalent thereof.

Furthermore, the gene expression construct may comprise at least two exon sequences from the human MBL gene or a functional equivalent thereof. More preferably the gene expression construct comprises at least three exon sequences from the human MBL gene or a functional equivalent thereof. When comprising more  
5 than one exon, the exon sequences are preferably aligned as in the human MBL gene.

Although preferred that the sequence comprises intron sequences, it may for some applications be convenient that the expression construct comprises a cDNA sequence encoding a MBL subunit or a functional equivalent thereof.  
10

The invention features the use of MBL gene expression constructs rather than MBL cDNA constructs for expression of rMBL in mammalian cell lines or transgenic animals to obtain recombinant MBL with structural properties under non-denaturing and denaturing conditions being substantially similar to natural human MBL. By "recombinant human MBL" is meant human MBL which is expressed from engineered nucleic acids and by "MBL gene expression constructs" is meant an expression vector suitable for expression in mammalian cell lines, which contains exon sequences and at least one intron sequence from the human MBL gene or from MBL genes of other animal species, such as but not limited to chimpanzees and rhesus monkeys.  
15  
20

Preferably, the DNA sequences encode a polypeptide sequence as shown in SEQ ID NO: 1 or a functional equivalent, whereby a functional equivalent is as defined above. SEQ ID NO:1 corresponds to the MBL sequence having database accession  
25 NO: P11226. The equivalent may be obtained by a modification of the peptide sequence shown as SEQ ID NO: 1, such as a sequence processing a corresponding property as the sequences mentioned in the present invention, but wherein one or more amino acids have been substituted with others. Preferably a functional equivalent contains conservative substitutions, i.e. where one or more amino acids  
30 are substituted by an amino acid having similar properties, such that a person skilled in the art of protein chemistry will expect the secondary and tertiary structure of the protein to be unchanged. Amino acids suitable for conservative substitutions include those having functionally similar side chains. For example, hydrophobic residues: e.g. glycine, alanine, valine, leucine, isoleucine and methionine may replace another  
35 such residue. Similarly, conservative substitutions may involve interchanging hydro-

philic residues: (e.g.: arginine and lysine, glutamine and asparagine, threonine and serine), basic residues (e.g., lysine, arginine and histidine), and/or acidic residues (e.g., aspartic acid and glutamic acid). Functional equivalents may also, or alternatively, be modified by for example the deletion or addition of amino acids, or the chemical modification of amino acids, as long as the function of the polypeptide is preserved.

The isolated MBL peptide including any functional equivalents thereof, may in one embodiment comprise at least 80 amino acid residues, such as at least 100 amino acid residues, such as at least 150 amino acid residues, such as at least 200 amino acid residues, for example at least 220 amino acid residues, such as at least 250 amino acid residues.

In a preferred embodiment the expression vector is suitable for expression in mammalian cell lines or transgenic animals, which contains exon sequences and at least one intron sequence from the human MBL gene or from MBL genes of other animal species, such as, but not limited to, chimpanzees and rhesus monkeys. In one embodiment the host cell culture is cultured in a transgene animal. By a transgenic animal in this context is meant an animal which has been genetically modified to contain and express the human MBL gene or fragments or mimics hereof.

In a preferred embodiment the expression construct of the present invention comprises a viral based vector, such as a DNA viral based vector, a RNA viral based vector, or a chimeric viral based vector. Examples of DNA viruses are cytomegalovirus, Herpes Simplex, Epstein-Barr virus, Simian virus 40, Bovine papillomavirus, Adeno-associated virus, Adenovirus, Vaccinia virus, and Baculo virus.

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the nucleic acid molecule of the invention may be ligated to an adenovirus transcription/translation control complex, for example, the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (for example, region E1 or E3) will result in a recombinant virus that is viable and capable of expressing a MASP-3 gene product in infected hosts (for example, see

Logan and Shenk, *Proc. Natl. Acad. Sci. USA* 81:3655-3659, 1984). Specific initiation signals may also be required for efficient translation of inserted nucleic acid molecules. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of the coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., *Methods in Enzymol.* 153:516-544, 1987).

Examples of RNA virus are Semliki Forest virus, Sindbis virus, Poko virus, Rabies virus, Influenza virus, SV5, Respiratory Syncytial virus, Venezuela equine encephalitis virus, Kunjin virus, Sendai virus, Vesicular stomatitisvirus, and Retroviruses.

Examples of chimetic viruses are Adeno-virus, Sindbis virus and Adenovirus – adeno-associated virus.

Regarding specific vectors reference is made to Makrides, S.C., "Components of vectors for Gene Transfer and Expression in Mammalian Cells", which is hereby incorporated by reference.

In particular, an Epstein-Barr virus origin of replication or functional derivatives or mimics hereof including the pREP9 vector is used.

In one aspect the invention provides an expression construct encoding human MBL, featured by comprising one or more intron sequences from the human MBL gene including functional derivatives hereof. Additionally, it contains a promoter region selected from genes of virus or eukaryotes, including mammalia and insects.

The promoter region is preferably selected to be different from the human MBL promoter, and preferably in order to optimize the yield of MBL and size distribution of MBL oligomers, the promoter region is selected to function most optimally with the vector and host cells in question.

5

In a preferred embodiment the promoter region is selected from a group comprising Rous sarcoma virus long terminal repeat promoter, and cytomegalovirus immediate-early promoter, and elongation factor-1 alpha promoter.

10

In another embodiment the promoter region is selected from genes of microorganisms, such as other viruses, yeasts and bacteriae.

15

In order to obtain a greater yield of recombinant MBL, the promoter region may comprise enhancer elements, such as the QBI SP163 element of the 5' end untranslated region of the mouse vascular endothelial growth factor gene.

The construct is used for transforming a host cell to obtain a host cell culture capable of expressing MBL.

20

The synthesis of the recombinant MBL may be by use of *in vitro* or *in vivo* cultures. The host cell culture is preferably an eucaryotic host cell culture. By transformation of an eukaryotic cell culture is in this context meant introduction of recombinant DNA into the cells. The expression construct used in the process is characterised by having the MBL encoding region selected from mammalian genes including human genes and genes with big resemblance herewith such as the genes from the chimpanzee. The expression construct used is furthermore featured by the promoter region being selected from genes of virus or eukaryotes, including mammalian cells and cells from insects.

25

The present invention provides thus recombinant MBL, which is a form of MBL similar to natural human MBL, in that it in its purified form has a molecular size distribution profile closer to the natural human MBL than known up till now.

30

The process for producing recombinant MBL according to the invention is characterised in that the host cell culture is preferably eukaryotic, and for example a mammalian cell culture. A preferred host cell culture is a culture of human kidney cells

35

and in an even more preferred form the host cell culture is a culture of human embryonal kidney cells (HEK cells). The invention features the use of HEK 293 cell lines for production of recombinant human MBL. By "HEK 293 cell lines" is meant any cell line derived from human embryonal kidney tissue such as, but not limited to, the cell lines deposited at the American Type Culture Collection with the numbers CRL-1573 and CRL-10852.

Other cells may be chick embryo fibroblast, hamster ovary cells, baby hamster kidney cells, human cervical carcinoma cells, human melanoma cells, human kidney cells, human umbilical vascular endothelium cells, human brain endothelium cells, human oral cavity tumor cells, monkey kidney cells, mouse fibroblast, mouse kidney cells, mouse connective tissue cells, mouse oligodendritic cells, mouse macrophage, mouse fibroblast, mouse neuroblastoma cells, mouse pre-B cell, mouse B lymphoma cells, mouse plasmacytoma cells, mouse teratocarcinoma cells, rat astrocytoma cells, rat mammary epithelium cells, COS, CHO, BHK, 293, VERO, HeLa, MDCK, WI38, and NIH 3T3 cells.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (for example, glycosylation) and processing (for example, cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. The mammalian cell types listed above are among those that could serve as suitable host cells.

In another aspect the present invention provides MBL that is prepared by recombinant DNA technology in e.g. mammalian cells or in transgenic animals. More specifically, the invention concerns recombinant MBL (rMBL), which is synthesized by

- preparing a gene expression construct as defined above encoding a human MBL polypeptide or a functional equivalent thereof,

- transforming a host cell culture with the construct,

5

- cultivating the host cell culture, thereby obtaining expression and secretion of the polypeptide into the culture medium, followed by

- obtaining a culture medium comprising human recombinant MBL.

10

Furthermore, the invention relates to the synthesis of MBL by

(a) preparation of an expression construct encoding human MBL;

15

(b) transformation of a eukaryotic cell culture with said expression construct and thereby obtain an eukaryotic recombinant host cell culture;

(c) growth of said recombinant host cell culture either in vitro or in form of a transgenic animal and thereby express said human MBL;

20

(d) harvest of said expressed human MBL and purification hereof by means of affinity chromatography as described above.

25

The host cell culture may be cultured in any suitable culture medium. Example of culture medium are RPMI-1640 or DMEM supplemented with, e.g., insulin, transferrin, selenium, and foetal bovine serum

30

The invention further consists of a step for purification or isolation of human MBL, such as human MBL from culture supernatants or from body fluids or tissue from transgenic animals by use of carbohydrate affinity chromatography as described above. In a preferred embodiment of the invention the affinity chromatography is performed by means of matrices of mannose, hexose or N-acetyl-glucosamine derivatized matrices, which are suitable for affinity chromatography as described above. In particular, an affinity chromatography is used, in which the matrices have been derivatized with mannose. Previously the use of matrices derivatized with

35

mannan has been employed to harvest recombinant MBL from culture supernatant. While mannan-derivatized matrices binds both high and low molecular weight forms of MBL, the use of matrices derivatized as described above, such as with mannose offers an surprising advantage in the purification of recombinant MBL as this matrix selectively bind the form of recombinant MBL that resemble natural MBL. The degree of similarity to the natural MBL is measured to be more than 50% in analysis of the size distribution by SDS-PAGE followed by protein staining of the gel as known in the prior art, see e.g. Ma *et al.* (1997)

Purified recombinant MBL is in this context to be understood as recombinant MBL purified from cell culture supernatants or body fluids or tissue from transgenic animals purified by use of carbohydrate affinity chromatography.

The process of isolating or purifying a composition of human MBL oligomers having a size distribution at least 50 % identical with naturally occurring plasma MBL preferably comprises

- obtaining a preparation of human MBL oligomers,
- subjecting said preparation to affinity chromatography using a carbohydrate-derivatized matrix, said carbohydrate-derivatized matrix having a two-fold greater affinity for tetramers, pentamers and/or hexamers of MBL than for dimers of MBL, and
- obtaining an eluate comprising the isolated human recombinant MBL composition.

The present invention provides a novel form of recombinant MBL composition comprising oligomers of MBL subunits, the size distribution profile of the oligomers being at least 50 % identical to the size distribution of naturally occurring plasma human MBL. In a preferred embodiment the size distribution is at least 60 % identical, such as 70 % identical, such as 80 % identical, such as 90 % identical, such as 95 % identical, to naturally occurring MBL is provided.

It is preferred that the higher oligomers of the subunit, such as tetramers, pentamers and/or hexamers are dominating the composition. Thus, in the composition the ratio



of tetramers, pentamers, and/or hexamers to subunits and/or dimers is preferably at least 2:1, preferably at least 5:1.

5 In a preferred embodiment, the ratio of the sum of tetramers, pentamers and hexamers to the sum of subunits and dimers is preferably at least 2:1, more preferably at least 5:1.

10 When estimating the size distribution of the oligomers of the MBL composition the size distribution is assessed by Western blotting on a SDS-PAGE. Hereby it may be seen that 50 % means that more than 50 % of the rMBL has an apparent molecular weight higher than 200 kDa when analysed by SDS-PAGE and/or Western blot.

15 The recombinant MBL composition may be purified by any suitable means from the culture medium, such as by any physico-chemical isolating method, including but not limited to filtration methods, chromatography, such as ion-exchange chromatography based on size, gel permeation chromatography or affinity chromatography. The recombinant MBL composition is preferably purified from the culture medium by means of affinity chromatography as discussed above.

20 The functionality of the recombinant MBL composition is preferably resembling the functionality of plasma or serum MBL. In the present context the functionality of MBL is meaning the capability of activating the complement system as discussed above in relation to functional equivalents. The functionality may be expressed as the specific activity of MBL, such as units of MBL activity per ng MBL. The functionality the  
25 recombinant MBL composition as expressed as specific activity is preferably at least 25 % of the specific activity of MBL purified from serum, such as at least 50 % of the specific activity of MBL purified from serum, more preferred at least 75 % of the specific activity of MBL purified from serum.

30 The MBL composition according to the invention is substantially free from any impurities naturally associated with the MBL when produced in a native host organism, such as from any impurities naturally associated with the MBL purified from serum. By a native host organism is meant that MBL is produced by a cell normally expressing MBL.

35

The eluant obtained from the affinity chromatography may be used as such for preparing a pharmaceutical composition, or the eluant may be subjected to further purification steps before being used.

- 5      The MBL composition obtained by the present invention may be used for the preparation of a pharmaceutical composition for the prevention and/or treatment of various diseases or conditions.

10      In addition to the MBL oligomers, the pharmaceutical composition may comprise a pharmaceutically acceptable carrier substance and/or vehicles.

15      In particular, a stabilising agent may be added to stabilise the MBL proteins. The stabilising agent may be a sugar alcohol, saccharide, protein and/or amino-acids. An example of a stabilising agent may be albumin or maltose.

Other conventional additives may be added to the pharmaceutical composition depending on administration form for example.

20      In one embodiment the pharmaceutical composition is in a form suitable for injections. Conventional carrier substances, such as isotonic saline, may be used.

In another embodiment the pharmaceutical composition is in a form suitable for pulmonal administration, such as in the form of a powder for inhalation or creme or fluid for topical application.

25      The present invention is based upon the synthesis of a novel form of recombinant MBL, which form is closer to the natural human MBL than achieved up till now and which can be synthesised by use of *in vitro* or *in vivo* technology. Based upon the evidence for the important role of MBL in the immune defence, this provided form of recombinant MBL offers the surprising possibility of treatment of conditions such as cancer and of infections in connection with immunosuppressive chemotherapy. The structural differences between the previously reported preparations of recombinant MBL compared to the natural form of MBL made any such treatment unlikely. Also, the application of rMBL similar to natural MBL in said treatment represents a great

30

advantage over the application of known MBL, in particular plasma-derived human MBL, since the treatment with rMBL confers a much reduced risk of viral infection.

5 The treatment needs not be a treatment of a diagnosed disease, disorder or condition in a presently or apparently need of treatment but may be used to prevent the disease or condition to occur.

10 A treatment in this context may comprise cure and/or prophylaxis of e.g. the immune system and reproductive system by humans and by animals having said functional units acting in this respect like those in humans. By conditions to be treated are not necessarily meant conditions presently known to be in a need of treatment, but comprise generally any condition in connection with current and/or expected need or in connection with an improvement of a normal condition. In particular, the treatment is a treatment of a condition of deficiency of MBL.

15

In another aspect of the present invention the manufacture is provided of a medicament consisting of said pharmaceutical compositions of MBL, including compositions of rMBL fragments or mimics hereof intended for treatment of conditions comprising cure and/or prophylaxis of conditions of diseases and disorders of e.g. the  
20 immune system and reproductive system by humans and by animals having said functional units acting like those in humans.

25

Said diseases, disorders and/or conditions in need of treatment with the compounds of the invention comprise eg treatment of conditions of deficiency of MBL, treatment of cancer and of infections in connection with immunosuppressive chemotherapy including in particular those infections which are seen in connection with conditions during cancer treatment or in connection with implantation and/or transplantation of organs. The invention also comprises treatment of conditions in connection with recurrent miscarriage.

30

Thus, in particular the pharmaceutical composition may be used for the treatment and/or prevention of clinical conditions selected from infections, MBL deficiency, cancer, disorders associated with chemotherapy, such as infections, diseases associated with human immunodeficiency virus (HIV), diseases related with congenital or  
35 acquired immunodeficiency. More particularly, chronic inflammatory demyelinating

polyneuropathy (CIDP, Multifocal motoric neuropathy, Multiple sclerosis, Myasthenia Gravis, Eaton-Lambert's syndrome, Opticus Neuritis, Epilepsy; Primary antiphospholipid syndrome; Rheumatoid arthritis, Systemic Lupus erythematosus, Systemic scleroderma, Vasculitis, Wegner's granulomatosis, Sjögren's syndrome, Juvenile rheumatoid arthritis; Autoimmune neutropenia, Autoimmune haemolytic anaemia, Neutropenia; Crohn's disease, Colitis ulcerous, Coeliac disease; Asthma, Septic shock syndrome, Chronic fatigue syndrome, Psoriasis, Toxic shock syndrome, Diabetes, Sinuitis, Dilated cardiomyopathy, Endocarditis, Atherosclerosis, Primary hypo/agammaglobulinaemia including common variable immunodeficiency, Wiskot-Aldrich syndrome and serve combined immunodeficiency (SCID), Secondary hypo/agammaglobulinaemia in patients with chronic lymphatic leukaemia (CLL) and multiple myeloma, Acute and chronic idiopathic thrombocytopenic purpura (ITP), Allogenic bone marrow transplantation (BTM), Kawasaki's disease, and Guillan-Barre's syndrome.

The route of administration may be any suitable route, such as intravenously, intramuscularly, subcutaneously or intradermally. Also, pulmonal or topical administration is envisaged by the present invention.

In particular the MBL composition may be administered to prevent and/or treat infections in patients having clinical symptoms associated with congenital or acquired MBL deficiency or being at risk of developing such symptoms. A wide variety of conditions may lead to increased susceptibility to infections in MBL-deficient individuals, such as chemotherapy or other therapeutic cell toxic treatments, cancer, AIDS, genetic disposition, chronic infections, and neutropenia.

It appears that cancer patients treated by chemotherapy are often susceptible to infection due to adverse effects of the drug regime on cells of the immune system, which is the background for the use of MBL therapy in the treatment of this condition. The observed low plasma concentrations of MBL (below 500 ng/mL) are indicative for an increased susceptibility to clinical significant infections, and the immune defence of these patients can be reinforced by administration of recombinant or natural plasma-derived MBL.

The pharmaceutical composition may thus be administered for a period before the onset of administration of chemotherapy or the like and during at least a part of the chemotherapy.

5 The MBL composition may be administered as a general "booster" before chemotherapy, or it may be administered to those only being at risk of developing MBL deficiency. The group of patients being at risk may be determined by measuring the MBL level before treatment and only subjecting those to treatment whose MBL level is below a predetermined level. The limit for determining a low MBL level is evaluated to be below 500 ng/ml for most groups. The MBL level may be determined by time resolved immunofluorescent assay as described in Example 9, ELISA, RIA or nephelometry.

10 Another indication for administering MBL is when the MBL level is below 50 % of the normal level, such as below 300 ng/ml, or below 200 ng/ml.

The MBL composition is administered in suitable dosage regimes, in particular it is usually administered at suitable intervals, eg. once or twice a week during chemotherapy.

20 Normally from 1-100 mg is administered per dosage, such as from 2-10 mg, mostly from 5-10 mg per dosage. Mostly about 0.1 mg/kg body weight is administered.

25 Thus, in one aspect the invention concerns MBL, including rMBL, fragments or mimics hereof for use in the treatment of cancer and of conditions of diseases and disorders of e.g. the immune system and reproductive system, said treatment consisting of creation, reconstitution, enhancing and/or stimulating the opsonic and/or bactericidal activity of the complement system, i.e. enhancing the ability of the immune defence to recognise and kill microbial pathogens.

30 Furthermore, an aspect of the present invention is the use of a recombinant composition according to the present invention in a kit-of-parts further comprising another medicament. In particular the other medicament may be an anti-microbial medicament, such as antibiotics.

35

Concerning miscarriage, it has been reported that the frequency of low plasma levels of MBL is increased in patients with otherwise not explained recurrent miscarriages, which is the background for lowering of the susceptibility to miscarriage by a reconstitution of the MBL level by administration of recombinant MBL in these cases.

As to the nature of compounds of the invention, it appears, that in its broad aspect, the present invention relates to compounds which are able to act as opsonins, that is, able to enhance uptake by macrophages either through direct interaction between the compound and the macrophage or through mediating complement deposition on the target surface. A particular example hereof is MBL, a fragment or a mimic hereof. The present invention is based upon the disclosure of a synthesis of a recombinant human MBL which appears to be closer to the structure of the natural human MBL than achieved in the past.

The invention has now been explained and accounted for in various aspects and in adequate details, but additionally it will be illustrated below by figure 1 and 2 and the non-limiting examples of preferred embodiments.

## BRIEF DESCRIPTION OF THE FIGURE

Figure 1 shows purified recombinant and native MBL compared analysed in the non-reduced state by SDS-PAGE and silver staining (stacking gel included). Lane 'S' was loaded with 24 ng of natural MBL (MO-04, The State Serum Institute), Lane 'HEK' with 60 ng of rMBL produced in HEK 293EBNA cells and Lane 'Hyb' with 12 ng of rMBL produced in Sp2/OAg14 cells (supplied by Dr. R.A.B. Ezekowitz). Arrow shows the position of the predominant form in the hybridoma cell-produced rMBL. Although the amount rMBL in Lane 'HEK' is 5 times higher than in Lane 'Hyb', no band 55 kDa band can be seen in Lane 'HEK', suggesting a significant difference in the disulfide bridge formation of the two rMBL subunits. ( As discussed in Example 6

Figure 2 shows a sketch of a preferred expression construct according to the invention viz. the MBL/pREP9 construct as discussed in Example 1.

Figure 3 shows MBL concentrations in fractions (stated as elution volume) from gel permeation chromatography analysis (Example 7).

5 Figure 4 shows a Western blot analysis of rMBL purified by mannose-TSK beads, mannan-TSK beads, mannose-Sepharose beads, mannan-Sepharose beads and underivatized Sepharose 4B beads. For comparison unfractionated culture supernatant from MBL/pREP9 transfected cells was included (Example 3).

10 Figure 5 shows a Western blot of two preparations of rMBL analysed in the non-reduced state: 50 ng rMBL produced according to the present invention ('293 EBNA cells') and 50 ng rMBL preparations produced according to the method described by Super *et al.*, 1992 ('Sp2/OAg14 cells'). Natural MBL purified from human serum as described by Lu *et al.* 1990 ('Natural MBL') (Example 6).

## 15 EXAMPLES

### EXAMPLE 1

#### *Design of the MBL gene expression construct:*

20 Human genomic DNA was isolated from 20 mL of blood drawn into EDTA. The EDTA/blood was mixed with 80 mL of cold (4 °C) 10 mM Tris-HCl, 5 mM MgCl<sub>2</sub>, 1% (v/v) Triton X-100, 0.32 mM sucrose, and left to incubate at 4 °C for 30 min with occasional agitation. The sample was centrifuged at 1000×g for 30 min at 4 °C, followed by discharge of the supernatant and a brief rinse of the nuclei-containing pellet in approximately 10 mL of 0.9% (w/v) of NaCl. The collected nuclei were resuspended in 6 mL of 75 mM NaCl, 24 mM EDTA [pH 8.0], and 460 µL of 10% (w/v) SDS and 1 mg pronase (cat.no: 165921, Boehringer-Mannheim, Mannheim, Germany) was added. After o/n incubation at RT with gentle agitation, 2 mL of a saturated (~ 6 M) NaCl solution was added. Following vigorous agitation, the debris was  
25 removed by centrifugation at 1000×g. Isopropanol was added 1:1 to the supernatant and the vial was gently shaken until the DNA precipitate appeared. The thread-like precipitate was collected on a sealed Pasteur pipette, washed on the sealed tip in 70% (v/v) ethanol, air-dried and finally resuspended in 1 mL of TE-buffer. PCR amplification of the MBL gene was carried out with a sense-primer modified to contain  
30 an *Xho*I site: 5'-AGATTAACCTTCCtGAGTTTTCTCACACC-3'. The anti-sense

primer was modified to contain a *Bam*HI site: 5'-  
TAACggaTCCACTCCAATAATACATACAC-3' (restriction sites engineered into the  
sequences are underlined and modified basepairs compared to the natural gene  
sequence as published by Sastry *et al.* (1989) are shown as lower case letters in both  
5 primer sequences. Primers were produced by DNA technology, Aarhus, Denmark).  
The sense and anti-sense primers were located in the 5' and 3' UTRs respectively.  
Reaction conditions for the PCR consisted of 200 µM dATP, 200 µM dCTP, 200 µM  
dGTP, 200 µM dTTP (cat.no. 1969064, Boehringer-Mannheim), reaction buffer at 1×  
strength, 0.75 µL of enzyme (cat.no. 1732641, Expand High Fidelity™, Boehringer-  
10 Mannheim, reaction buffer supplied with enzyme), genomic DNA (100 ng), and wa-  
ter to a final volume of 50 µL. The PCR thermal program performed 1 cycle at 96 °C  
for 3 min, 10 cycles of 94 °C for 15 s, 60 °C for 30 s, and 72 °C for 5 min, followed  
by 20 cycle of 94 °C for 15 s, 60 °C for 30 s, and 68 °C for 5 min with a time incre-  
ment of 20 s per cycle, followed by a final elongation step at 72 °C for 5 min (Omn-  
15 E™ thermal cycler, Hybaid, Ashford, UK). Cloning of the 6.2 kb PCR product into the  
pCR2 vector by use of the TA cloning kit™ (cat.no. K2000-01, Invitrogen, Leek, The  
Netherlands) was carried out according to the manufactures' recommendations. The  
*MBL* gene was isolated from the pCR2 by digesting the vector with *Not*I and *Bam*HI  
enzymes (cat.nos. 15441-025 & 15201-023, GibcoBRL, Paisley, UK) for 6 h at 37 °C  
20 in an appropriate buffer. The insert DNA, *i.e.*, the 5'-*Not*I-*MBL*-*Bam*HI-3' fragment,  
was isolated from an 1% (w/v) agarose gel by use of Pharmacia's Bandprep™ kit  
(cat.no. 27-9285-01, Pharmacia, Uppsala, Sweden). The pREP9 vector (cat.no.  
V009-50, Invitrogen) was digested as described for the *MBL*/pCR2 vector and the  
restriction product, *i.e.*, the linearised vector, was likewise isolated from agarose to  
25 minimise contamination with undigested vector. In a final volume of 10 µL, 1 µL (~  
100 ng) of digested pREP9 vector, 4 µL (~ 400 ng) of 5'-*Not*I-*MBL*-*Bam*HI-3', ligation  
buffer at 1× strength and 20 units of T4 ligase (cat.no. 202S, New England Biolabs,  
Beverly, MA, reaction buffer supplied with enzyme) was incubated o/n at 14 °C. *E.*  
*coli* TOPF10 cells were made transformation competent by CaCl<sub>2</sub> permeabilising  
30 and transformed with the ligation product by heat-shock as described by Hanahan  
(1983). The bacteria were spread onto LB-agar plates supplemented with 50 µg  
ampicillin/mL, and colonies appeared after o/n incubation at 37 °C.

Figure 2 shows a sketch of a preferred expression construct according to the inven-  
35 tion viz. the *MBL*/pREP9 construct. The PCR amplified (the location of sense and



antisense primers are indicated black with arrows) part of the *MBL* gene contained the four exons, including the entire known 3' untranslated of exon 4 as determined by Sastry *et al.* 1989. The fragment was merged with the expression vector, named pREP9, in the *NotI* and *Bam* HI endonuclease restriction sites (the *EcoRV*, *XbaI*, *BglII*, *XmnI*, *ClaI*, *StuI* and *SacI* restriction endonuclease sites in the vector sequence are also indicated). Transcription of the *MBL* fragment cloned into the pREP9 expression vector was controlled by the Rous sarcoma virus long terminal repeat promoter (*P<sub>RSV</sub>*) located upstream to the cloning site (direction of the transcription for elements of the vector are indicated with arrow heads) and with a simian virus 40 (SV40) polyadenylation site. Bacterial propagation, that is, production of vector DNA in *E. coli*, was obtained through an ampicillin resistance marker (Amp) and a ColE1 prokaryot 'origin of replication'. Maintenance of the vector in HEK293EBNA cells was conferred by the Epstein-Barr virus origin of replication (*OriP*) and expression of the Epstein-Barr virus nuclear antigen 1 (EBNA-1), which attaches the vector to the host cell chromosomes.

## EXAMPLE 2

### *Expression of recombinant MBL in mammalian cells:*

HEK 293EBNA cells, grown until confluence in 150 cm<sup>2</sup> flasks (cat.no. 9075, TPP AG) containing DMEM (Biological Industries) supplemented with 10% FBS, glutamin, 200 µg G418/mL (Geneticin™, cat.no. G9516, Sigma) and antibiotics (10,000 units penicillin and 0.1% (w/v) streptomycin), were harvested by trypsination and seeded in a four fold lower density (~25% confluence) into 150 cm<sup>2</sup> flasks (cat.no. 90150, TPP) 24 h prior to transfection. Three hours prior to transfection all medium was renewed. In a total volume of 1680 µL, 60 µg of the MBL/pREP plasmid DNA (reference is made to Example 1) was mixed with 150 mM NaCl, 1 mM EDTA, 10 mM Tris-HCl (pH 7.12), 268 mM CaCl<sub>2</sub>. The DNA, calcium solution was added into 1680 µL of 50 mM HEPES, 250 mM NaCl, 1.5 mM Na<sub>2</sub>HPO<sub>4</sub>+NaH<sub>2</sub>PO<sub>4</sub> adjusted to pH 7.12. The cells were incubated for 14-16 h with the DNA/Ca·PO<sub>4</sub> precipitate, rinsed twice in PBS and further incubated with RPMI-1640 medium (50 mL per bottle) supplemented with glutamin, antibiotics (penicillin and streptomycin) and insulin-transferrin-selenium (ITS) solution (cat.no. 51300-44, GibcoBRL) for 6-8 d.

## EXAMPLE 3

Purification of rMBL by use of carbohydrate-derivatized matrices.

- 5 Fractogel TSK HW-75 beads (cat.no. 14985, Merck KGaA, Darmstadt, Germany) were activated by mixing 50 mL of beads with 50 mL of 0.5 M  $\text{Na}_2\text{CO}_3$  (pH 11) and 10 mL of vinyl sulfone (cat.no. V370-0, Aldrich, Milwaukee, WI), followed by incubation with agitation for 1½ h at RT. The beads were collected on a glass filter and washed once in  $\text{H}_2\text{O}$  and once in 0.5 M  $\text{Na}_2\text{CO}_3$  (pH 11). Beads were resuspended
- 10 in 0.5 M  $\text{Na}_2\text{CO}_3$  (pH 11) and mannose added to a final concentration of 10% (w/v). The mixture was left to incubate with agitation o/n at RT. Following rinse in  $\text{H}_2\text{O}$ , residual reactive groups were blocked by incubating the beads in 0.1 M ethanolamine (pH 9) for 2 h. After a rinse in  $\text{H}_2\text{O}$  and TBS, 5 mL of mannose-coupled TSK-
- 15 75 was packed on a chromatography column and washed in 15 mL of 0.1 M glycine (pH 3.0) and equilibrated in TBS/0.05% (v/v) Tween-20, 2 mM  $\text{CaCl}_2$  until UV-absorption remained stable. Culture medium from *MBL/pREP9* transfected cells, cleared by centrifugation at 5000×g, was passed over the column at 0.4 mL/min. The column was washed in 75 mL of TBS, 2 mM  $\text{CaCl}_2$ , and the bound rMBL eluted
- 20 in TBS, 5 mM EDTA and collected in fractions of 500 µL. To prepare TSK beads with mannan (purified from yeast as described by Nakajima & Ballou, 1974), the beads were activated as described above and incubated with 25 mg mannan/mL 0.5 M  $\text{Na}_2\text{CO}_3$  (pH 11), followed by the same treatment as for preparation of mannose-
- 25 derivatized beads. Sepharose 4B (cat.no. 17-0120-01, Pharmacia, Uppsala, Sweden) beads were derivatized with mannose and mannan as described for the TSK beads. Eluates from the three matrices were analysed Western blotting as described in Example A, loading 7 ng of rMBL purified by mannose-TSK beads, mannan-TSK beads, mannose-Sepharose beads, and mannan-Sepharose beads into separate lanes of the SDS-PAGE gel. For comparison unfractionated culture supernatant corresponding to 7 ng of rMBL was loaded in a lane. The Western blot is shown in
- 30 Figure 4.

## EXAMPLE 4

*Analysis of MBL under non-denaturing conditions by gel permeation chromatography*

Permeation chromatography of purified rMBL or culture medium containing rMBL was performed on a Superose-6 column (Superose 6™ HR 10/30, cat.no. 17-0537-01, Pharmacia) equilibrated in 5 mM EDTA, TBS, 0.01% (v/v) Tween-20 [pH 7.4]. A sample volume of 100 µL was passed over the column with a flow rate of 0.5 mL/min. Fractions were collected 5 mL post sample injection in volumes of 250 µL.

10 EXAMPLE 5

*Analysis of MBL under denaturing conditions by SDS-PAGE/silver-staining*

SDS-PAGE 4%-20% gradient gels were prepared and used in electrophoresis as described by Jensen *et al.* (1997). The procedure for silver staining was adopted from Nesterenko *et al.* (1994). The PAGE gels were fixed in 100 mL 50% (v/v) acetone, 6.25 mL trichloroacetic acid, 0.85% (v/v) formaldehyde for 15 min, followed by rinsing three times in H<sub>2</sub>O, and washing for 15 min in H<sub>2</sub>O. The gel was incubated in 100 mL of 50% (v/v) acetone for 15 min followed by incubation for 1 min in 0.67 mM Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, and three rinses in H<sub>2</sub>O. Impregnation of the gel with silver nitrate was carried out in 15 mM AgNO<sub>3</sub>, 0.9% (v/v) formaldehyde, followed by rinsing three times in H<sub>2</sub>O. The gel was developed by incubating in 0.19 mM Na<sub>2</sub>CO<sub>3</sub>, 0.9% (v/v) formaldehyde, 0.67 mM Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> for approx. 3 min. The precipitation was stopped by incubation of the gel for 3 min in 1% (v/v) acetic acid and preserved in 25% (v/v) ethanol, 3% (v/v) glycerol.

25

EXAMPLE 6

*Analysis of rMBL by SDS-PAGE followed by Western blotting*

30 Tris buffered saline (TBS) and phosphate buffered saline (PBS), all adjusted to pH 7.4 were prepared as described by Sambrook *et al.* (1989). For blocking non-specific protein interactions, the buffers were supplemented with 0.05% (v/v) Tween-20 (TBS/Tw and PBS/Tw). SDS-PAGE 4%-20% gradient gels were prepared and used in electrophoresis as described by Jensen *et al.* (1997). 50 ng of rMBL pro-

duced in HEK 293EBNA cells (prepared according to the present invention), 50 ng of rMBL prepared as described by Super *et al.* (1992), and 50 ng of MBL prepared from human plasma (MO012, State Serum Institute) was loaded onto the gel in the non-reduced state. Proteins were transferred onto Amersham's Hybond™-P membrane (cat.no. RPN303F) by semi-dry blotting in 50 mM Tris-base, 40 mM glycine, 3.7% (w/v) SDS, 20% (v/v) ethanol for 60 V×h. Non-specific protein interactions were blocked by incubating the membrane with 0.1% Tween-20 for ½ h. For detection of MBL, the membrane was incubated with a monoclonal antibody raised against human MBL (Hyb 131-1, State Serum Institute) diluted to 1 µg/ml in TBS, 0.05% Tween-20, 1 mM EDTA, 1 mg HSA/mL (cat.no. 44 05 11, State Serum Institute), 1 mg human IgG/mL (cat.no. 00 7740, Centeon Pharma GmbH, Marburg, Germany) o/n at RT. After 3 washes in TBS/Tw buffer, the membrane was incubated with HRP conjugated rabbit anti mouse IgG (cat.no. P0260, Dako A/S, Copenhagen, Denmark), diluted 2,500 fold in TBS/Tw, 1 mM EDTA with 100 µg human IgG/mL for 2 h at RT. Finally, the membrane was washed 5 times in TBS/Tw and developed with Pierce's chemiluminescence substrate (SuperSignal™, cat.no. 34080, Pierce, Rockford, IL) on photographic films (Kodak, NY).

#### EXAMPLE 7

20

Analysis of rMBL by gel permeation chromatography

Gel permeation chromatography of purified rMBL or culture medium containing rMBL was performed on a Superose-6 column (Superose 6™ HR 10/30, cat.no. 17-0537-01, Pharmacia) equilibrated in 5 mM EDTA, TBS, 0.01% (v/v) Tween-20 [pH 7.4]. A sample volume of 100 µL (corresponding to 100 ng of rMBL or natural MBL) was passed over the column with a flow rate of 0.5 mL/min. Fractions were collected 5 mL post sample injection in volumes of 250 µL. The fractions were diluted 2 fold in TBS/Tw, 10 mM EDTA and analysed by a time-resolved immunofluorometric assay (TRIFMA) as described in Example 8.

30

#### EXAMPLE 8

35

Analysis of rMBL by a time-resolved immunofluorometric assay (TRIFMA)

Flourosorp™ microtitre plates (cat.no. 437958, Nunc, Kamstrup, Denmark) were coated o/n with 100 µL (per well) of MAb 131-1 anti-MBL (Statens Serum Institut, Copenhagen, Denmark) at 5 µg/mL PBS and washed trice in TBS/Tw. A standard serum with a known MBL concentration (3.6 µg MBL/mL) was diluted 20 fold in 10 mM EDTA, TBS/Tw and used as such as well as in further 5-fold dilutions with duplicate wells, each receiving 100 µL of the dilution. Three control sera, one with a high conc. of MBL (1.2 µg MBL/mL), one with a medium concentration of MBL (250 ng MBL/mL), and one with a low concentration of MBL (50 ng MBL/mL), were applied diluted 20 fold in TBS/Tw/EDTA. An MBL deficient serum was likewise diluted 20 fold and added to the plate as a negative control. Culture supernatants, either FBS containing or serum-free, were typically diluted 20 and 100 fold. After o/n incubation, the plate was washed trice in TBS/Tw and each well received 100 µL of Eu<sup>3+</sup>-labelled MAb 131-1 anti-MBL at 125 ng/mL 25 µM EDTA, TBS/Tw. Labelled antibody was prepared essentially according to Wallac's protocol (Wallac, Turku, Finland). Development and measurement of bound europium was carried out by standard procedures for time resolved immunofluorometry as described elsewhere (Hemmila *et al.*, 1993).

## REFERENCES

- Davies, E.J., Snowden, N., Hillarby, M.C., Carthy, D., Grennan, D.M., Thomson, W. & W.E. Ollier (1995) Mannose-binding protein gene polymorphism in systemic lupus erythematosus. *Arthritis. Rheum.* **38**:110-114.
- 5 Drickamer, K., J., Dordal, M.S. & L. Reynolds (1986) Mannose-binding proteins isolated from rat liver contain carbohydrate-recognition domains linked to collagenous tails. *J. Biol. Chem.* **261**: 6878-6887.
- 10 Christiansen, O.B., Kilpatrick, D.C., Souter, V., Warming, K., Thiel, S. & J.C. Jensenius (1999) Mannan-binding lectin deficiency is associated with unexplained recurrent miscarriage. *Scand. J. Immunol.* **49**:193-196.
- 15 van Emmerik, L.C., Kuijper, E.J., Fijen, C.A.P., Dankert, J. & S. Thiel (1994) Binding of mannan-binding protein to various bacterial pathogens of meningitis. *Clin. Exp. Immunol.* **97**:411-416.
- 20 Garred, P., Richter, C., Andersen, Å.B., Madsen, H.O., Mtoni, I., Svejgaard, A. & J. Shao (1997a) Mannan-binding lectin in the sub-saharan HIV and tuberculosis epidemics. *Scand. J. Immunol.* **46**:204-208.
- 25 Garred, P., Madsen, H.O., Balslev, U., Hofmann, B., Pedersen, C., Gerstoft, J. & A. Svejgaard (1997b) Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. *Lancet* **349**:236-240.
- Guo, N., Mogues, T., Weremowicz, S., Morton, C.C. & K.N. Sastry (1998) The human ortholog of rhesus mannose-binding protein-A gene is an expressed pseudo-gene that localizes to chromosome 10. *Mamm. Genome* **9**:246-249.
- 30 Hanahan, D. (1983) Studies on transformation of *Escherichia coli* with plasmids. *J. Mol. Biol.* **166**:557-580.
- 35 Hartshorn, K.L., Sastry, K., Brown, D., White, M.R., Okarma, T.B., Lee, Y.-M. & A.I. Tauber (1993) Conglutinin acts as an opsonin for influenza A viruses. *J. Immunol.* **151**:6265-6273.

- Haurum, J., Thiel, S., Jones, I.M., Fischer, P., Laursen, S.B. & J.C. Jensenius (1993) Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. *AIDS* 7:1307-1313.
- 5 Hemmila, I., Makkala, V.M., Latva, M. & P. Kiilholma (1993) Di- and tetracarboxylate derivatives of pyridines, bipyridines and terpyridines as luminogenic reagents for time-resolved fluorometric determination of terbium and dysprosium. *J. Biochem. Biophys. Methods*. 26:283-290
- 10 Holmskov, U., Holt, P., Reid, K.B.M., Willis, A.C., Teisner, B. & J.C. Jensenius (1993a) Purification and characterization of bovine mannan-binding protein. *Glycobiology* 3:147-153.
- 15 Holmskov, U., Malhotra, R., Sim, R.B. & J.C. Jensenius (1994) Collectins: collagenous C-type lectins of the innate immune defense system. *Immunol. Today* 15 :67-74.
- Huang, Y., Kong, Y., Wang, Y., Qi, G. & C. Lu (1996) Stable expression of anti-HPV 20 16 E7-ribozyme in CV-1 cell lines. *Chin. J. Biotechnol.* 12:215-20.
- Iobst, S.T., Wormald, M.R., Weis, W.I., Dwek, R.A. & K. Drickamer (1994) Binding of sugar ligands to Ca(2+)-dependent animal lectins. I. Analysis of mannose binding by site-directed mutagenesis and NMR. *J. Biol. Chem.* 269:15505-15511.
- 25 Ip, W.K., Chan, S.Y., Lau, C.S. & Y. L. Iau (1998) Association of systemic lupus erythematosus with promoter polymorphisms of mannose-binding lectin gene. *Arthritis Rheum* 41:1663-1668.
- 30 Janeway, C.A., Travers, P., Walport, M. & J.D. Capra (1999) *Immunobiology* (4<sup>th</sup> ed.). Churchill Livingston, Edinburg, 634 pp.

- Ji, Y.-H., Fujita, T., Hatsuse, H., Takahashi, A., Matsushita, M. & M. Kawakami (1993) Activation of the C4 and C2 components of complement by a proteinase in serum bactericidal factor, ra-reactive factor. *J. Immunol.* 150:571-578.
- 5 Kawai, T., Suzuki, Y., Eda, S., Ohtani, K., Kase, T., Sakamoto, T., Uemura, H. & N. Wakamiya (1998) Molecular and biological characterization of rabbit mannan-binding protein. *Glycobiology* 8:237-244.
- 10 Kawasaki, T., Etoh, R. & I. Yamashina (1978) Isolation and characterisation of a mannan-binding protein from rabbit liver. *Biochem. Biophys. Res. Comm.* 3:1018-1024.
- Kilpatrick, D.C. (1997) Mannan binding protein is sera positive for rheumatoid factor. *Br. J. Rheumatol.* 36:207-209.
- 15 Kuhlman, M., Joiner, K. & R.A.B. Ezekowitz (1989) The human mannose-binding protein function as an opsonin. *J. Exp. Med.* 169:1733-1745.
- 20 Kurata, H., Cheng, H.M., Kozutsumi, Y., Yokota, Y. & T. Kawasaki (1993) Role of the collagen-like domain of the human serum mannan-binding protein in the activation of complement and the secretion of this lectin. *Biochem. Biophys. Res. Comm.* 191:1204-1210.
- 25 Kurata, H., Sannoh, T., Kozutsumi, Y., Yokota, Y. & T. Kawasaki (1994) Structure and function of mannan-binding proteins isolated from human liver and serum. *J Biochem.* 115:1148-1154.
- 30 Lau, Y.L., Lau, C.S., Chan, S.Y., Karlberg, J. & M.W. Turner (1996) Mannose-binding protein in Chinese patients with systemic lupus erythematosus. *Arthritis Rheum* 39 :706-708.
- 35 Laursen, S.B., Hedemand, J.E., Thiel, S., Willis, A.C., Skriver, E., Madsen, P.S. & J.C. Jensenius (1995) Collectin in a non-mammalian species: isolation and characterization of mannan-binding protein (MBP) from chicken serum. *Glycobiology* 5:553-561.



- Laursen, S.B., Dalgaard, T.S., Thiel, S., Lim, B.L., Jensen, T.V., Juul-Madsen, H.R., Takahashi, A., Hamana, T., Kawakami, M. & J.C. Jensenius (1998) Cloning and sequencing of a cDNA encoding chicken mannan-binding lectin (MBL) and comparison with mammalian analogues. *Immunology* 93:421-430.
- 5
- Law, S. K. A. & K.B.M. Reid (1995) Complement, IRL Press, Oxford.
- Lipscombe, R.J., Lau, Y.L., Levinsky, R.J., Sumiya, M., Summerfield, J.A. & M.W. Turner (1992a) Identical point mutation leading to low levels of mannose binding protein and poor C3b mediated opsonisation in Chinese and Caucasian populations. *Immunol. Lett.* 32:253-257.
- 10
- Lipscombe, R.J., Sumiya, M., Hill, A.V., Lau, Y.L., Levinsky, R.J., Summerfield, J.A. & M.W. Turner (1992b) High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. *Hum. Mol. Genet.* 1:709-715.
- 15
- Lipscombe, R.J., Sumiya, M., Summerfield, J.A. & M.W. Turner (1995) Distinct physicochemical characteristics of human mannose-binding protein expressed by individuals of differing genotype. *Immunology* 85:660-667.
- 20
- Lu, J., Thiel, S., Wiedemann, H., Timpl, R. & K.B.M. Reid (1990) Binding of the pentamer/hexamer forms of mannan-binding protein to zymosan activates the pro-enzyme C1<sub>2</sub>C1s<sub>2</sub> complex, of the classical pathway of complement without involvement of C1q. *J. Immunol.* 144:2287-2294.
- 25
- Ma, Y., Yokota, Y., Kozutsumi, Y. & T. Kawasaki (1996) Structural and functional roles of the amino-terminal region and collagen-like domain of human serum mannan-binding protein. *Biochem. Mol. Biol. Int.* 40:965-974.
- 30
- Ma, Y., H. Shida & T. Kawasaki (1997) Functional expression of human mannan-binding proteins (MBPs) in human hepatoma cell lines infected by recombinant vac-

cinia virus: post-translational modification, molecular assembly, and differentiation of serum an liver MBP. *J.Biochem. (Tokyo)* **122**: 810-818.

5 Ma, Y., Uemura, K., Oka, S., Kozutsumi, Y., Kawasaki, N. & T. Kawasaki (1999)  
Antitumor activity of mannan-binding protein in vivo as revealed by a virus expres-  
sion system: mannan-binding protein-dependent cell-mediated cytotoxicity. *PNAS*  
**96**:371-375.

10 Madsen, H.O., Garred, P., Kurtzhals, J.A., Lamm, L.U., Ryder, L.P., Thiel, S. & A.  
Svejgaard (1994) A new frequent allele is the missing link in the structural polymor-  
phism of the human mannan-binding protein. *Immunogenetics* **40**:37-44.

15 Madsen, H.O., Garred, P., Thiel, S., Kurtzhals, J.A., Lamm, L.U., Ryder, L.P., & A.  
Svejgaard (1995) Interplay between promoter and structural gene variants control  
basal serum level of mannan-binding protein. *J. Immunol.* **155**:3013-3020.

Malhotra, R., Haurum, J.S., Thiel, S. & R.B. Sim (1994) Binding of human collectins  
(SP-A and MBP) to influenza virus. *Biochem. J.* **304**:455-461.

20 Matsushita, M. & T. Fujita (1992a) Activation of the classical complement pathway  
by mannose-binding protein in association with a novel C1s-like protease. *J. Exp.*  
*Med.* **176**:1497-1502.

25 Matsushita, M., Ezekowitz, R.A.B. & T. Fujita (1995a) The Gly-54→Asp allelic form  
of human mannose-binding protein (MBP) fails to bind MBL-associated serine pro-  
tease. *Biochem. J.* **311**:1021-1023.

30 Mizuno, Y., Kozutmi, Y., Kawasaki, T. & I. Yamashina (1981) Isolation and charac-  
terization of a mannan-binding protein from rat liver. *J. Biol. Chem.* **256**:4247-4252.

Mogues, T., Ota, T., Tauber, A.I. & K.N. Sastry (1996) Characterization of two man-  
nose-binding protein cDNAs from rhesus monkey (*Macaca mulatta*): structure and  
evolutionary implications. *Glycobiology* **6**:543-550.

Makrides, S.C., "Components of vectors for Gene Transfer and Expression in Mammalian Cells"

- 5 Nakajima, T. & C.E. Ballou (1974) Characterization of the carbohydrate fragments obtained from *Saccharomyces cerevisiae* mannan by alkaline degradation. *J. Biol. Chem.* 249:7679-7684
- 10 Ng, K.K., Drickamer, K. & W.I. Weis (1996) Structural analysis of monosaccharide recognition by rat liver mannose-binding protein. *J. Biol. Chem.* 271:663-674 .
- Nielsen, S.L., Andersen, P.L., Koch, C., Jensenius, J.C. & S. Thiel (1995) The level of the serum opsonin, mannann-binding protein in HIV-1 antibody-positive patients. *Clin. Exp. Med.* 100:219-222.
- 15 Ohta, M., Okada, M., Yamashina, I. & T. Kawasaki (1989) The mechanism of carbohydrate-mediated complement activation by the serum mannann-binding protein. *J. Biol. Chem.* 265:1980-1984.
- 20 Ohtani, K., Suzuki, Y., Eda, S., Kawai, T., Kase, T., Keshi, H., Sakai, Y., Yamamoto, S., Sakamoto, T. & N. Wakamiya (1999) High-level and effective production of human mannann-binding lectin (MBL) in Chinese hamster ovary (CHO) cells. *J. Immunol. Methods.* 222:135-44 .
- 25 Oka, S., Ikeda, K., Kawasaki, T. & I. Yamashina (1985) Isolation and characterization of mannann-binding proteins from chicken liver. *Arch. Biochem. Biophys.* 241:95-105.
- 30 Oka, S., Ikeda, K., Kawasaki, T. & I. Yamashina (1988) Isolation and characterization of two distinct mannann-binding proteins from rat serum. *Arch. Biochem. Biophys.* 260:257-266.
- 35 Pastinen, T., Liitsola, K., Niini, P., Salminen, M. & A.-C. Syvänen (1998) Contribution of the CCR5 and MBL genes to susceptibility to HIV type 1 infection in the Finnish population. *AIDS Res. Hum. Retroviruses* 14:695-698.

- Reddy, P.S. & R.B. Corley (1998) Assembly, sorting, and exit of oligomeric proteins from the endoplasmic reticulum. *Bioessays* 20:546-554.
- 5     Sastry, K., Herman, G.A., Day, L., Deignan, E., Bruns, G., Morton, C.C. & R.A.B. Ezekowitz (1989) The human mannose-binding protein gene. *J. Exp. Med.* 170:1175-1189.
- 10    Sato, T., Endo, Y., Matsushita, M. & T. Fujita (1994) Molecular characterization of a novel serine protease involved in activation of the complement system by mannose-binding protein. *Int. Immunol.* 6:665-669.
- 15    Schweinle, J.E., Nishiyasu, M., Ding, T.Q., Sastry, K., Gillies, S.D. & R.A.B. Ezekowitz (1993) Truncated forms of mannose-binding protein multimerize and bind to mannose-rich salmonella montevideo but fail to activate complement in vitro. *J. Biol. Chem.* 268:364-370.
- 20    Sheriff, S., Chang, C.Y. & R.A.B. Ezekowitz (1994) Human mannose-binding protein carbohydrate recognition domain trimerizes through a triple  $\alpha$ -helical coiled-coil. *Structural biol.* 1:789-794.
- Soothill, J.F. & B.A. Harvey (1976) Defective opsonization. A common immunity deficiency. *Arch. Dis. Child.* 51:91-99.
- 25    Stover, C.M., Thiel, S., Thelen, M., Lynch, N.J., Vorup-Jensen, T., Jensenius, J.C. & W.J. Schwaebler (1999) Two constituents of the initiation complex of the mannan-binding lectin activation pathway of complement are encoded by a single structural gene. *J. Immunol.* 162:3481-3490 .
- 30    Sumiya, S., Super, M., Tabona, P., Levinsky, R.J., Arai, T., Turner, M.W. & J.A. Summerfield (1991) Molecular basis of opsonic defect in immunodeficient children. *Lancet* 337:1569-1570.

- Super, M., Thiel, S., Lu, J., Levinsky, R.J. & M.W. Tumer (1989) Association of low levels of mannan-binding protein with a common defect opsonisation. *Lancet* ii:1236-1239.
- 5 Super, M., Gillies, S.D., Foley, S., Sastry, K., Schweinle, J.E., Silverman, V.J. and R.A.B. Ezekowitz (1992) Distinct and overlapping functions of allelic forms for human mannose-binding protein. *Nature Genet.* 2:50-55.
- 10 Tabona, P., Mellor, A. & J.A. Summerfield (1995) Mannose binding protein is involved in first-line host defence: evidence from transgenic mice. *Immunology* 85:153-159.
- 15 Takada, F., Takayama, Y., Hatsuse, H. & M. Kawakami (1993) A new member of the C1s family of complement proteins found in a bactericidal factor, ra-reactive factor, in human serum. *Biochem. Biophys. Res. Commun.* 196:1003-1009.
- 20 Takayama, Y., F. Takada, Takahashi, A. and M. Kawakami (1994) A 100-kDa protein in the C4-activating component of ra-reactive factor is a new serine protease having module organisation similar to C1r and C1s. *J. Immunol.* 152: 2308-2316.
- Tan, F.K. & F. C. Arnett (1998) The genetics of lupus. *Curr. Opin. Rheumatol.* 10:399-408.
- 25 Taylor, M.E., Brickell, P.M., Craig, R.K. & J.A. Summerfield (1989) Structure and evolutionary origin of the gene encoding a human serum mannose-binding protein. *Biochem. J.* 262:763-771.
- 30 Thiel, S., Vorup-Jensen, T., Stover, C.M., Schwaeble, W., Laursen, S.B., Poulsen, K., Willis, A.C., Eggleton, P., Hansen, S., Holmskov, U., Reid, K.B. & J.C. Jensenius (1997). A second serine protease associated with mannan-binding lectin that activates complement. *Nature* 386:506-510.
- Turner, M.W. (1996) Mannose-binding lectin: the pluripotent molecule of the innate immune system. *Immunol. Today* 17:532-540.

- Valdimarsson, H., Stefansson, M., Vikingsdottir, T., Arason, G.J., Koch, C., Thiel, S. & J.C. Jensenius (1998) Reconstitution of opsonizing activity by infusion of mannan-binding lectin (MBL) to MBL-deficient humans. *Scand. J. Immunol.* **48**:116-23.
- 5
- Vorup-Jensen, T., Jensenius, J.C. & S. Thiel (1998) MASP-2, the C3 convertase generating protease of the MBLectin complement activating pathway. *Immunobiology* **199**: 348-357.
- 10
- Voss, T., Melchers, K., Scheirle, G. & K.P. Schäfer (1991) Structural comparison of recombinant pulmonary surfactant protein SP-A derived from two human coding sequences: implications for the chain composition of natural human SP-A. *Am. J. Respir. Cell Mol. Biol.* **4**:88-94.
- 15
- Weis, W.I., Drickamer, K. & W.A. Hendrickson (1992) Structure of a C-type mannose-binding protein complexed with an oligosaccharide. *Nature* **360**:127-134.
- Weis, W.I. & K. Drickamer (1994) Trimeric structure of a C-type mannose-binding protein. *Structure* **2**:1227-1240.

**CLAIMS:**

- 5 1. A process of producing a human recombinant mannan binding lectin (MBL) composition having a size distribution profile at least 50 % identical to natural occurring human, comprising the steps of:
- preparing a gene expression construct encoding human MBL peptide or a functional equivalent thereof,
  - 10 - transforming a host cell culture with the construct,
  - cultivating the host cell culture, thereby obtaining expression and secretion of the polypeptide into the culture medium, followed by
  - 15 - subjecting said culture medium to affinity chromatography using a carbohydrate-derivatized matrix, said carbohydrate-derivatized matrix having at least a two-fold greater affinity for tetramers, pentamers and/or hexamers of MBL subunit than for dimers of MBL subunit,
  - 20 - obtaining an eluate comprising the human recombinant MBL composition.
- 25 2. The process according to claim 1, wherein the gene expression construct comprises at least one intron sequence from the human MBL gene or a functional equivalent thereof.
- 30 3. The process according to claim 1, wherein the gene expression construct comprises at least two exon sequences from the human MBL gene or a functional equivalent thereof.
4. The process according to claim 1, wherein the gene expression construct comprises a cDNA sequence encoding a MBL subunit or a functional equivalent thereof.

5. The process according to claim 1, wherein the host cell culture is cultured *in vitro*.
- 5 6. The process according to claim 1, wherein the host cell culture is cultured *in vivo*.
7. The process according to claim 6, wherein the host cell culture is cultured in a transgene animal.
- 10 8. The process according to claim 1, wherein the host cell culture is an eucaryotic host cell culture.
9. The process according to claim 8, wherein the host cell culture is a mammalian host cell culture.
- 15 10. The process according to claim 1, wherein the matrix as such has substantially no affinity to MBL.
11. The process according to claim 10, wherein the matrix as such is carbohydrate free.
- 20 12. The process according to claim 11, wherein the matrix as such is consisting of a non-carbohydrate containing polymer material.
- 25 13. The process according to claim 12, wherein the matrix is consisting of plastic beads.
14. The process according to claim 1, wherein the isolation of the polypeptide composition is performed on a hexose-derivatized matrix.
- 30 15. The process according to claim 14, wherein the isolation of the polypeptide composition is performed on a mannose-derivatized matrix.
- 35 16. The process according to the claim 1, wherein the carbohydrate-derivatized matrix has substantially no affinity for subunits and/or dimers of MBL subunits.



17. The process according to any of the preceding claims, wherein the carbohydrate-derivatized matrix has affinity for substantially only tetrameric recombinant MBL subunits.
- 5
18. The process according to any of the preceding claims, wherein the carbohydrate-derivatized matrix has affinity for substantially only pentameric recombinant MBL subunits.
- 10
19. The process according to any of the preceding claims, wherein the carbohydrate-derivatized matrix has affinity for substantially only hexameric recombinant MBL subunits.
- 15
20. The process according to any of the preceding claims, wherein the carbohydrate-derivatized matrix has affinity for substantially only tetramers, pentamers, and/or hexamers of recombinant MBL subunits.
- 20
21. The process according to any of the preceding claims, wherein the size distribution profile is substantially identical to naturally occurring human plasma MBL.
22. A recombinant human MBL composition comprising oligomers of MBL subunits, the size distribution profile of the oligomers being at least 50 % identical to the size distribution of naturally occurring plasma human MBL.
- 25
23. The composition according to claim 22, wherein the size distribution is at least 95 % identical to the size distribution of naturally occurring plasma human MBL.
24. The composition according to claim 22; wherein the ratio of tetramers, pentamers and/or hexamers to dimers of MBL subunits is at least 2:1, preferably at least
- 30
- 5:1.
25. The composition according to claim 22, wherein MBL composition is substantially free from any impurities naturally associated with the MBL when produced in a native host organism.
- 35

26. The composition according to any of the claims 22-25, wherein the size distribution is assessed by SDS-PAGE and/or Western Blotting.
- 5 27. The composition according to any of the claims 22-26, being in a non-denatured state.
28. The composition according to any of the claims 22-26, being in a denatured state.
- 10 29. The composition according to claim 22, wherein the MBL subunit is assembled of three peptide sequences comprising the sequence as shown i SEQ ID NO:1 or a functional equivalent thereof.
- 15 30. A gene expression construct encoding a recombinant human mannan-binding lectin (MBL) polypeptide, comprising
- at least one intron sequence from the human MBL gene or a functional equivalent thereof,
  - 20 - at least one exon sequence from the human MBL gene or a functional equivalent thereof,
  - a promoter region different from the human MBL promoter, and
  - 25 - an expression vector.
31. The gene expression construct according to claim 30, wherein the promoter region is selected from genes of eucaryotes, such as mammals and insects.
- 30 32. The gene expression construct according to claim 30, wherein the promoter region is selected from viral genes.
33. The gene expression construct according to claim 32, wherein the promoter region is selected from a group comprising Rous sarcoma virus long terminal repeat

promoter, and cytomegalovirus immediate-early promoter, and elongation factor-1 alpha promoter.

5 34. The gene expression construct according to claim 30, wherein the promoter region is selected from genes of microorganisms, such as viruses, yeast or bacteria.

35. The gene expression construct according to claim 30, wherein the promoter region comprises enhancer elements.

10 36. The gene expression construct according to claim 30, wherein the vector is a pREP9 vector.

37. A process of producing a human recombinant mannan binding lectin (MBL), comprising the steps of:

15

- preparing a gene expression construct as defined in any of claims 30-36 encoding a human MBL polypeptide or a functional equivalent thereof,

- transforming a host cell culture with the construct,

20

- cultivating the host cell culture, thereby obtaining expression and secretion of the polypeptide into the culture medium, followed by

- obtaining a culture medium comprising human recombinant MBL.

25

38. A process of isolating a composition of human MBL oligomers having a size distribution at least 50 % identical with naturally occurring plasma MBL comprising

- obtaining a preparation of human MBL oligomers,

30

- subjecting said preparation to affinity chromatography using a carbohydrate-derivatized matrix, said carbohydrate-derivatized matrix having a two-fold greater affinity for tetramers, pentamers, and/or hexamers of MBL subunit than for dimers of MBL subunit, and

35

- obtaining an eluate comprising the isolated human recombinant MBL composition.

5 39. The process according to claim 38, wherein the matrix as such has substantially no affinity to MBL.

40. The process according to claim 39, wherein the matrix as such is carbohydrate free.

10 41. The process according to claim 39, wherein the matrix as such is consisting of a non-carbohydrate containing polymer material.

42. The process according to claim 41, wherein the matrix is consisting of plastic beads.

15 43. The process according to claim 38, wherein the isolation of the polypeptide composition is performed on a mannose-matrix.

20 44. The process according to claim 38, wherein the isolation of the polypeptide composition is performed on a hexose-matrix.

45. The process according to the claim 38, wherein the carbohydrate-derivatized matrix has substantially no affinity for subunits and/or dimers of MBL subunits.

25 46. The process according to claim 38, wherein the the carbohydrate-derivatized matrix has affinity for substantially only tetramers, pentamers and/or hexamers of MBL subunits.

30 47. A pharmaceutical composition comprising a human recombinant MBL composition as defined in any of the claims 22-29, optionally further comprising a pharmaceutically acceptable carrier substance.

48. The composition according to claim 47, in a form suitable for injections.

49. The composition according to claim 48, wherein the carrier substance is saline, human serum albumin, or mannose.

50. The composition according to the claims 47, in a form suitable for pulmonal administration.

51. The composition according to claim 50, in the form of a powder for inhalation.

52. The composition according to claim 47, in the form of a creme or lotion for topical application

53. Use of a gene expression construct as defined in the claims 30-36 for the production of a human recombinant MBL composition.

54. Use of a human recombinant MBL composition as defined in the claims 22-29 for the production of a pharmaceutical composition.

55. The use of a composition according to claim 54, for the production of a pharmaceutical composition for the treatment, in an individual, of clinical conditions selected from infections, MBL deficiency, cancer, disorders associated with chemotherapy, miscarriages, disorders associated with neutropenia, and human immunodeficiency virus (HIV).

56. The use according to claim 55, wherein the pharmaceutical composition is administered intravenously, intramuscularly, subcutaneously, or intradermally.

57. The use according to claim 55, wherein the pharmaceutical composition is administered pulmonally.

58. The use according to claim 55, wherein the pharmaceutical composition is administered topically

59. The use according to claim 55, wherein the pharmaceutical composition is administered prophylactically before initiation of chemotherapy or other therapeutic cell toxic treatments.

60. The use according to claim 59, wherein the treatment is continued for a suitable period after initiation of the of chemotherapy or other therapeutic cell toxic treatment.

5 61. The use according to claim 60, wherein the serum MBL level in the individual is measured before initiating treatment.

62. The use according to claim 61, wherein the serum MBL level is below 50 % of the normal level before initiating treatment.

10

63. The use according to claim 55, wherein the amount of MBL composition administered is from 1-100 mg/dosage.

1 / 5

**Fig. 1**




Fig. 2






Fig. 3




Fig. 4





Fig. 5



## SEQUENCE LISTING

<110> Jensenius, Jens Christian and Thiel, Steffen

<120> Recombinant Human Mannan-Binding Lectin

<130> p 433 DK00

<140>

<141>

<160> 1

<170> PatentIn Ver. 2.1

<210> 1

<211> 248

<212> PRT

<213> Homo sapiens

<300>

<308> swissprot: P11226

<400> 1

Met Ser Leu Phe Pro Ser Leu Pro Leu Leu Leu Ser Met Val Ala  
1 5 10 15

Ala Ser Tyr Ser Glu Thr Val Thr Cys Glu Asp Ala Gln Lys Thr Cys  
20 25 30

Pro Ala Val Ile Ala Cys Ser Ser Pro Gly Ile Asn Gly Phe Pro Gly  
35 40 45

Lys Asp Gly Arg Asp Gly Thr Lys Gly Glu Lys Gly Glu Pro Gly Gln  
50 55 60

Gly Leu Arg Gly Leu Gln Gly Pro Pro Gly Lys Leu Gly Pro Pro Gly  
65 70 75 80

Asn Pro Gly Pro Ser Gly Ser Pro Gly Pro Lys Gly Gln Lys Gly Asp  
85 90 95

Pro Gly Lys Ser Pro Asp Gly Asp Ser Ser Leu Ala Ala Ser Glu Arg  
100 105 110

Lys Ala Leu Gln Thr Glu Met Ala Arg Ile Lys Lys Trp Leu Thr Phe  
115 120 125

Ser Leu Gly Lys Gln Val Gly Asn Lys Phe Phe Leu Thr Asn Gly Glu  
130 135 140

Ile Met Thr Phe Glu Lys Val Lys Ala Leu Cys Val Lys Phe Gln Ala  
145 150 155 160

Ser Val Ala Thr Pro Arg Asn Ala Ala Glu Asn Gly Ala Ile Gln Asn  
165 170 175

Leu Ile Lys Glu Glu Ala Phe Leu Gly Ile Thr Asp Glu Lys Thr Glu  
180 185 190

Gly Gln Phe Val Asp Leu Thr Gly Asn Arg Leu Thr Tyr Thr Asn Trp  
195 200 205

Asn Glu Gly Glu Pro Asn Asn Ala Gly Ser Asp Glu Asp Cys Val Leu  
210 215 220

Leu Leu Lys Asn Gly Gln Trp Asn Asp Val Pro Cys Ser Thr Ser His  
225 230 235 240

Leu Ala Val Cys Glu Phe Pro Ile  
245

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 00/00246

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KURATA HIROSHI ET AL: "Structure and function of mannan-binding proteins isolated from human liver and serum." JOURNAL OF BIOCHEMISTRY (TOKYO), vol. 115, no. 6, 1994, pages 1148-1154, XP000938557 ISSN: 0021-924X cited in the application	1,3-5,8, 9,14, 16-29, 38,44-46
Y	the whole document --- -/--	2,30-36

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

5 September 2000

Date of mailing of the international search report

12/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Espen, J

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/DK 00/00246

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>MA YONG ET AL: "Functional expression of human mannan-binding proteins (MBPs) in human hepatoma cell lines infected by recombinant vaccinia virus: Post-translational modification, molecular assembly, and differentiation of serum and liver MBP." JOURNAL OF BIOCHEMISTRY (TOKYO), vol. 122, no. 4, October 1997 (1997-10), pages 810-818, XP000938556 ISSN: 0021-924X cited in the application</p>	1,3-5,8, 9,14, 16-29, 38,44-46
Y	<p>the whole document</p>	2,30-36
X	<p>MA YONG ET AL: "Structural and functional roles of the amino-terminal region and collagen-like domain of human serum mannan-binding protein." BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL, vol. 40, no. 5, 1996, pages 965-974, XP000861821 ISSN: 1039-9712 cited in the application</p>	1,3-5,8, 14, 16-29, 38,44-46
Y	<p>the whole document</p>	2,30-36
X	<p>OHTANI KATSUKI ET AL: "High-level and effective production of human mannan-binding lectin (MBL) in Chinese hamster ovary (CHO) cells." JOURNAL OF IMMUNOLOGICAL METHODS, vol. 222, no. 1-2, 1 January 1999 (1999-01-01), pages 135-144, XP004152435 ISSN: 0022-1759 cited in the application</p>	1,3-5,8, 9,14, 16-29, 38,44-46
Y	<p>the whole document</p>	2,30-36
Y	<p>TAYLOR ME ET AL: "Structure and evolutionary origin of the gene encoding a human serum mannose-binding protein" BIOCHEM JOURNAL, vol. 262, 1989, pages 763-771, XP000861866 great britain the whole document</p>	2,30-36
X	<p>YOKOTA Y ET AL: "Oligomeric structures required for complement activation of serum mannan - binding proteins." JOURNAL OF BIOCHEMISTRY, (1995 FEB) 117 (2) 414-9. , XP000938572 the whole document</p>	22-29

-/--

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/DK 00/00246

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>VALDIMARSSON H ET AL: "Reconstitution of opsonizing activity by infusion of mannan-binding lectin (BML) to MBL-deficient humans."  SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 48, no. 2, August 1998 (1998-08), pages 116-123, XP000911946  ISSN: 0300-9475  cited in the application  the whole document</p>	<p>47-49,  54-56,  61-63</p>
X	<p>KILPATRICK DAVID C: "Mannan binding lectin and its clinical significance."  EUROPEAN JOURNAL OF CELL BIOLOGY, vol. 74, no. SUPPL. 46, 1997, page 18  XP000912114  7th International Lectin Meeting; Wuerzburg, Germany; September 24-27, 1997  ISSN: 0171-9335  abstract</p>	<p>47, 54</p>
X	<p>MA YONG ET AL: "Antitumor activity of mannan-binding protein in vivo as revealed by a virus expression system: Mannan-binding protein-dependent cell-mediated cytotoxicity."  PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 2, 19 January 1999 (1999-01-19), pages 371-375, XP000911748  Jan. 19, 1999  ISSN: 0027-8424  cited in the application  the whole document</p>	<p>54, 55</p>
X	<p>WO 89 01519 A (CHILDRENS HOSPITAL CORP)  23 February 1989 (1989-02-23)  example 3</p>	<p>47, 54-56</p>



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK 00/00246

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8901519 A	23-02-1989	AT 165980 T	15-05-1998
		AU 2426288 A	09-03-1989
		DE 3856180 D	18-06-1998
		DE 3856180 T	03-09-1998
		DK 43890 A	19-02-1990
		EP 0375736 A	04-07-1990
		JP 2504581 T	27-12-1990
		JP 2868777 B	10-03-1999
		NO 900745 A	06-04-1990
		US 5270199 A	14-12-1993

THIS PAGE BLANK (CS:10)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

THIS PAGE ON LINE